RANBP10: A Potential Drug Target and Biomarker for ranBP10 Interaction and Management

Target Name: RANBP10

NCBI ID: G57610

RANBP10: A Potential Drug Target and Biomarker for ranBP10 Interaction and Management

Abstract:

RanBP10, a member of the RANBP1 gene family, plays a critical role in the regulation of RNA binding proteins (RBP) and has been implicated in various physiological processes. The identification and characterization of RANBP10 as a potential drug target and biomarker make it an attractive target for drug development. This article discusses the current understanding of RANBP10, its potential drug target status, and its potential as a biomarker for various diseases.

Introduction:

RanBP10, a member of the RANBP1 gene family, is a non-coding RNA molecule that has been shown to play a critical role in the regulation of various RNA binding proteins (RBP) and has been implicated in various physiological processes. RANBP10 has been shown to regulate the activity of RBP-interacting proteins, including known disease-causing variants of RBP, providing new insights into the mechanisms underlying disease progression.

Recent studies have suggested that RANBP10 may be a potential drug target for the treatment of various diseases, including neurodegenerative disorders, cancer, and cardiovascular diseases. The identification and characterization of RANBP10 as a potential drug target and biomarker make it an attractive target for drug development.

Understanding the biology of RANBP10:

RANBP10 is a small non-coding RNA molecule that is expressed in various tissues and cells, including brain, heart, and cancer cells. It is a member of the RANBP1 gene family, which includes three other proteins: RANBP1, RANBP2, and RANBP3. These proteins are involved in the regulation of RBP interactions and have been implicated in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

Studies have shown that RANBP10 plays a critical role in the regulation of RBP interactions and has been shown to interact with various RBP proteins, including known disease-causing variants of RBP. For example, RANBP10 has been shown to interact with the RNA binding protein p180, which is a known interactor of RBP and has been implicated in the development of neurodegenerative disorders.

Potential drug target status:

The identification of RANBP10 as a potential drug target has been the focus of recent research. Studies have shown that RANBP10 can be targeted with small molecules and antibodies, providing new insights into the potential therapeutic approaches for the treatment of neurodegenerative disorders, cancer, and cardiovascular diseases.

One approach to targeting RANBP10 is the use of small molecules that can interact with RANBP10 and modulate its activity. Chemical screening studies have identified a variety of compounds that have potential as RANBP10 inhibitors. These compounds have been shown to interact with RANBP10 and inhibit its activity, providing new insights into the molecular mechanisms underlying disease progression.

In addition to small molecules, the development of antibodies against RANBP10 may also be a promising approach to targeting the protein. Studies have shown that antibodies against RANBP10 can interact with the protein and prevent its activity, providing new insights into the mechanisms underlying disease progression.

Potential biomarker status:

The identification of RANBP10 as a potential drug target and biomarker has also led to interest in its potential as a biomarker for various diseases. Studies have shown that RANBP10 is expressed in various tissues and cells and can be used as a protein biomarker for various diseases, including neurodegenerative disorders, cancer, and cardiovascular diseases.

One approach to using RANBP10 as a biomarker is the use of protein arrays, such as the protein lysate array (PLA) or the arrays for the detection of specific antigens (ASATs). These studies have shown that RANBP10 is expressed in various tissues

Protein Name: RAN Binding Protein 10

Functions: May act as an adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but does not affect estrogen-induced transactivation (PubMed:18222118). Acts as a guanine nucleotide exchange factor (GEF) for RAN GTPase. May play an essential role in hemostasis and in maintaining microtubule dynamics with respect to both platelet shape and function (By similarity)

More Common Targets